Triumph Capital Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$904 Buy
4
+3
+300% +$636 ﹤0.01% 1717
2026
Q2
$216 Hold
1
– – ﹤0.01% 1798
2026
Q1
$183 Buy
+1
New +$184 ﹤0.01% 1770

Other funds holding BIIB

Triumph Capital Management's BIIB Position: Q3 2026 in Review

Triumph Capital Management increased its Biogen (BIIB) stake by 300% in Q3 2026, buying an estimated $636 and bringing the position to 4 shares worth $904. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

Triumph Capital Management first reported a position in BIIB in Q1 2026 and has held it in 3 quarters since. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Triumph Capital Management held 4 shares of Biogen worth $904 as of Q3 2026.
  • Triumph Capital Management bought 3 Biogen shares in Q3 2026, an estimated $636.
  • Biogen made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1717 holding.
  • Triumph Capital Management first reported a position in Biogen in Q1 2026 and has held it in 3 quarters since.
  • 1,062 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.